Pay in 4 interest-free payments of $7.08 Learn more
Ships within 48 hours · Estimated delivery Nov 17 - Nov 22
PMC 2203276
While joint pain relief is not an FDA-approved indication for GLP-1 medications, emerging clinical observations and patient reports have prompted investigation into potential musculoskeletal benefits
In patients with locally advanced, metastatic, and/or refractory solid tumors and hematological malignancies, CB839 is being evaluated in open-label phase I clinical trials (NCT02071862, NCT02071888, NCT02771626)
Similarly, patients with active malignancy warrant careful consideration given theoretical concerns about angiogenic effects potentially affecting tumor growth, though preclinical evidence suggests context-dependent effects that may inhibit rather than promote tumor angiogenesis
Secondary infection as a risk factor for dengue hemorrhagic fever/dengue shock syndrome: an historical perspective and role of antibody-dependent enhancement of infection
US$ 22.19
US$ 23.10
US$ 29.58
US$ 20.30
US$ 20.66
US$ 21.79
